{"schema_version":"1","generated_at":"2026-11-20T06:16:47.851Z","data_as_of":null,"url":"https://www.findmykol.com/kol/matias-valsecchi","json_url":"https://www.findmykol.com/kol/matias-valsecchi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"matias-valsecchi","name":"Matias Valsecchi","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Huntington","state":"WV","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Matias Valsecchi is an Oncology physician. OpenAlex indexes 62 publications with 2,606 citations (h-index 18).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":62,"cited_by_count":2606,"h_index":18,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":83,"program_years":{"first":2021,"last":null},"rows_total":194,"shown":3,"withheld":191,"rows":[{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":374.5,"payment_count":17},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":211.6,"payment_count":11},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":202.17,"payment_count":4}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":26.4,"classes_total":6,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":13.4,"drugs":[{"name":"Anastrozole","share_pct":100}],"max_beneficiaries":55},{"class":"Thalidomide Analog","setting":"prescribed","share_pct":4.1,"drugs":[{"name":"Lenalidomide","share_pct":79.3},{"name":"Revlimid","share_pct":20.7}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":24.7,"classes_total":6,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":8.2,"drugs":[{"name":"Tramadol Hcl","share_pct":41.9},{"name":"Oxycodone Hcl","share_pct":35},{"name":"Fentanyl","share_pct":23.1}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":5.8,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":41}]},{"area":"Metabolism & gastrointestinal","share_pct":20.3,"classes_total":8,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":6.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":33},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":6,"drugs":[{"name":"Ondansetron Odt","share_pct":65.9},{"name":"Ondansetron Hcl","share_pct":34.1}],"max_beneficiaries":42}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":69.7,"facility_pct":30.3},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"PT1.08.03 Chemoradiation/Immunotherapy(IO) for Stageiii NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients","year":2025,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2025.09.1139","status":"verified"},{"title":"Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer","year":2024,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers16244207","status":"verified"},{"title":"A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.","year":2020,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.e22059","status":"verified"},{"title":"Precision therapeutic targeting of human cancer cell motility","year":2018,"journal":"Nature Communications","source_url":"https://doi.org/10.1038/s41467-018-04465-5","status":"verified"},{"title":"Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma","year":2017,"journal":"Ophthalmology","source_url":"https://doi.org/10.1016/j.ophtha.2017.08.017","status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":191,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}